Compare Align Technology, Inc. (ALGN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Smith & Nephew plc — how do they compare? Align Technology, Inc. trades at $173.29 (market cap $12.29B), while Smith & Nephew plc trades at $29.79 (market cap $12.54B). The key difference: Align Technology, Inc. and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.65% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | SNN | |
|---|---|---|
Market Cap | $12.29B | $12.54B |
Sector | Health | Health |
52-Week High | $197.51 | $38.70 |
52-Week Low | $124.88 | $28.73 |
Enterprise Value | $11.30B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $176.04, up 1.37% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported record Q2 2026 revenue of $1.06 billion, driven by strong clear aligner volume growth. Analyst sentiment is positive, with 73% recommending buy, and institutional activity shows mixed positioning amid strategic initiatives like board changes and patent wins in China.
The outlook remains favorable due to solid fundamentals and international expansion, but risks include competitive pressures in digital dentistry and reliance on North American market stability. Earnings growth and margin improvements are key catalysts, though valuation multiples near five-year lows suggest potential upside if execution continues.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
